Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy-optimized and toxicity-reduced therapy of metastatic colorectal cancer with cetuximab plus chemotherapy
2006-002744-28Phase 2Completed
- Sponsor
- iOMEDICO
- Start
- Jul 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of cetuximab in colorectal cancer (CRC) (2 arms), sponsored by iOMEDICO. Primary endpoint: Tumor progression. Started Jul 2006; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2006-002744-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002744-28.